Incyte's PD-1 priority review draws muted cheer — but analysts say it's all about getting a foot in the door
An eighth PD-(L)1 inhibitor is lining up at the FDA with the promise of bringing another big advance in cancer therapy. Just don’t expect it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
